Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2018) 56 P498 | DOI: 10.1530/endoabs.56.P498

1Clinic for Endocrinology, Diabetes and Diseases of Metabolism, University Clinical Center, Belgrade, Serbia; 2Institute for Gerontology and Palliative Care, Belgrade, Serbia; 3Clinic for Neurology, University Clinical Center, Belgrade, Serbia; 4Clinic for Cardiology, University Clinical Center, Belgrade, Serbia.


Introduction: Cognitive functions and mood (anxiety and depression) are often impaired in diabetes mellitus (DM). Dipeptidyl peptidase-4 inhibitor (DPP-4) has been shown to exert beneficial effects on insulin sensitivity and glycoregulation in T2DM patients. Introducing DPP-4 therapy leads to maintaining control of glucose levels which could ameliorate or slow down further cognitive and mood disorders impairment.

Aim: To evaluate influence of selective DPP-4 inhibitor therapy on cognitive functions, anxiety and depression in T2DM patients.

Method: This was controlled, prospective randomized study with 40 patients with T2DM patients on metformin therapy (63.3±7.4 yrs) and 34 healthy subjects (63.6±6 yrs) matched for age, gender and education. In all subjects, glycemia and Hba1c levels were measured before and six months after DPP-4 inhibitor therapy was introduced. Neuropsychological testing included MMSE, verbal and visual attention span, Trail Making tests A and B (TMTA, TMTB), Test for verbal divergent thinking–phonemic and category fluency (FF and CF), Hospital anxiety and depression scale.

Results: Glycemic control was statistically significantly improved after 6 months in 2DM group (Hba1c 8.32±1.4 vs 7.35±1.19, P<0.001). Some aspects of executive functions (TMTA, TMTB, visual span) were better after 6 months like (TMTA 52.45±20.98 vs 48.00±18.84, P=0.014, TMTB 96.06±26.08 vs 87.91±29.14, P=0.003, visual span 4.18±0.80 vs 4.64±0.90, P=0.009) as well as level of depression (HADSD 5.23±3.83 vs 4.27±3.03, P=0.009).

Conclusion: Improvement in cognitive functions and depression in T2DM patients after 6 months on DPP-4 inhibitor therapy were confirmed. Further clinical studies with longer follow up period are necessary to elucidate our findings.

Volume 56

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.